1Coleman RE.skeletal complications of malignancy[J].Cancer,1997,80(suppl):1588-1594.
2Berruti A,Dogliotti L,Bitossi R,et al.Incidence of skeletal complications in patients with bone metastastic prostate cancer and hormone refractory disease:predictive role of bone resorption and formation markers evaluated at baseline[J].J Urol,2000,164:1248-1253.
4Ghanem N,Uhl M,Brink I,et al.Diagnostic value of MRI in comparison to scintigraphy,PET,MS-CT and PET/CT for the detection of metastases of bone[J].Eur J Radiol,2005,55(1):41-55.
5Bury T,Barreto A,Daenen F,et al.Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer[J].Eur J Nucl Med,1998,25(9):1244-1247.
8Uematsu T,Yuen S,Yukisawa S,et al.Comparison of FDG PET and SPECT for Detection of Bone Metastases in Breast Cancer[J].AJR Am J Roentgenol,2005,184(4):1266-1273.
9Woitge HW,Pecherstorfer M,Li y,et al.Novel serum markers of bone resorption:clinical assessment and comparison with established urinary indicts[J].J Bone Miner Res,1999,14:792-801.
10Chung JH,Park MS,Kim YS,et al.Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer[J].Yonsei Med J,2005,46(3):388-393.
二级参考文献36
1Robinson RG, Preston DF, Spicer JA, et al. Radionuclide therapy of intractable bone pain:Emphasis on strontium 89[J] .Semin NM, 1992,22:28--32.
2Mcgivney WT, Crooks GM. The care of patients with severe chronic pain in terminal illness [ J ]. JAMA, 1984,251 : 1182-- 1188.
3Robinson RG, Spicer JA, Preston DF, et al. Treatment of metastatic bone pain with strontium 89[J ]. Nycl Med Biol, 1987, 14 : 219 -- 222.
4Maxon HR, Thomas SR, Hertaberg VS, et al. Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases[J ]. Semin Nucl Med, 1992,22: 33-- 40.
6Robinson RG, Preston DE, Baxter KG, et al. Clinical experience with strontium - 89 in prostatic and breast cancer patients[J].Semin Oncol, 1993, 20(3), Suppl 2:44-48.
7Harry R, Maxon III, Louis E, et al. Rhenium- 188(Sn) HEDP for treatment of osseous metastases[J ]. J Nucl Med, 1998, 39:659--663.
8Palmedo H, Guhlke S, Beets A, et al. Re- 188 - HEDP for pain palliation of bone metastases: First clinical results[J].Eur J Nucl Med, 1997,24:962.
9Knapp FF, Beets AL, Guhlke S, et al. Availability of rhenium - 188 from the alumina- based tungsten - 188/rhenium- 188 generator for preparation of rhenium-188- labeled radiopharmaceuticals for cancer treatment[J]. Anticancer Res, 1997, 17:1783-- 1795.
10Merrick MV, Merrick JM. Bone scintigraphy in lung cancer: a reappraisal. Br J Radiol, 1986, 59: 1185-1194.
